ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Sunday, November 17, 2024

10:30AM-12:30PM: Abstract Number: 0934

Screening NLRP3 Drug Candidates in Clinical Development:Lessons from Existing and Emerging Technologies

Innate Immunity Poster

10:30AM-12:30PM: Abstract Number: 0956

Secreted Frizzled-Related Protein 2 (sFRP2) Regulates Wnt Signaling to Affect Mesenchymal Transition of Lung Epithelial Cells Participates in Interstitial Lung Disease

Systemic Sclerosis & Related Disorders – Basic Science Poster I

10:30AM-12:30PM: Abstract Number: 1048

Self-Perception of Oral Health and Habits in Patients with Sjögren’s Syndrome, Rheumatoid Arthritis, and Systemic Lupus Erythematosus

Health Services Research – ACR/ARP Poster II

10:30AM-12:30PM: Abstract Number: 1491

Self-Reported Cognitive Function Among Older Adults with Systemic Lupus Erythematosus (SLE) Compared to Older Adults with Other Rheumatic and Musculoskeletal Conditions

SLE – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1123

Serological Elevation of IgG4: Clinical Correlation and Differential Diagnosis

Miscellaneous Rheumatic & Inflammatory Diseases Poster II

10:30AM-12:30PM: Abstract Number: 1317

Serum (1-3)-β-D-Glucan Levels in Juvenile Idiopathic Arthritis

Professional Education Poster

10:30AM-12:30PM: Abstract Number: 1631

Serum IL-6 Levels Correlate with Inflammatory Activity in Computerized Tomography Angiography Scans in Takayasu Arteritis

Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

10:30AM-12:30PM: Abstract Number: 1087

Sex Differences in Clinical Features and Mortality in Gout: A Nationwide Retrospective Cohort Study

Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II

10:30AM-12:30PM: Abstract Number: 1623

Sex Differences in Phenotypes and Imaging Examination in Giant Cell Arteritis: Data from the ARTESER Registry

Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

10:30AM-12:30PM: Abstract Number: 1471

Sex-related Differences in Efficacy and Safety Outcomes in Axial Spondyloarthritis Randomized Clinical Trials: A Systematic Literature Review and Meta-analysis

SpA Including PsA – Treatment Poster II

10:30AM-12:30PM: Abstract Number: 0891

Shared and Disease-Specific Mechanisms of Autoimmunity Using Single Cell Sequencing of Peripheral Immune Cells

Genetics, Genomics & Proteomics Poster

10:30AM-12:30PM: Abstract Number: 1046

Shifting Paradigms in Drug Spending: A Study of Medicare Part D versus Emerging Pharmacy Models in Rheumatology

Health Services Research – ACR/ARP Poster II

10:30AM-12:30PM: Abstract Number: 1160

Short Form-36 Psychometric Properties in Idiopathic Inflammatory Myopathies: Reliability, Validity and Responsiveness

Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster II

10:30AM-12:30PM: Abstract Number: 1440

Significant Indicators Identified for Carotid Doppler Ultrasound Use in Axial Spondyloarthritis Patients Without Conventional Cardiovascular Risk Factors

SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1148

Simplified Cutaneous Dermatomyositis Disease Area and Severity Index Activity Scores for Cutaneous Dermatomyositis

Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].